CUA Educational Content

Update on the treatment landscape for Renal Cell Carcinoma (RCC) in Canada

Featuring: Laurence Albiges (Gustave Roussy Institute and University of Paris Saclay)

By participating in this program, participants can expect to:

  • review new therapies available in RCC
  • examine the impact on sequencing and patient management with new therapies in RCC
  • review patient cases/determine which patient type would benefit from an IO/IO vs. IO/TKI therapy in RCC


    This activity is an Accredited Self-Assessment Program (Section 3) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada, and approved by the Canadian Urological Association. You may claim a maximum of 1 hour of credit.


    This program has received financial support from Pfizer in the form of an educational grant.